

Michael D Hill, O.C., MD MSc FRCPC (FAHA FESO FCAHS FRCS)
Professor, Dept Clinical Neuroscience & Hotchkiss Brain Institute
President, Canadian Neurological Sciences Federation
Senior Medical Director for Cardiovascular & Stroke Strategic Clinical Network, Alberta Health Services

Calgary Stroke Program
 Department of Clinical Neuroscience and Hotchkiss Brain Institute
 University of Calgary and Foothills Medical Centre
 Rm 2939, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, CANADA
 P: 403.210.7786
 E: michael.hill@ucalgary.ca

Education / Training

1986-89	BSc, Biochemistry, McGill University
1989-93	MD, University of Ottawa
1993-96	FRCPC, Internal Medicine, University of Ottawa Chief Resident, Ottawa Civic Hospital
1996-99	FRCPC, Neurology, University of Toronto Chief Resident, TWH & SHSC
1999-01	Clinical Stroke Fellowship, University of Calgary
1999-03	MSc, Clinical Epidemiology, University of Calgary

Employment History

2011-present	Professor of Neurology, Department of Clinical Neurosciences, University of Calgary [Cross-appointed to the Department of Community Health Sciences, Department of Medicine, Department of Radiology]
2009-2014	Associate Dean (Clinical Research), Faculty of Medicine, University of Calgary
2005-2011	Associate Professor of Neurology, Professor of Neurology, Department of Clinical Neurosciences, University of Calgary [Cross-appointed to the Department of Community Health Sciences, Department of Medicine, Department of Radiology]
2001-2005	Assistant Professor of Neurology, Professor of Neurology, Department of Clinical Neurosciences, University of Calgary [Cross-appointed to the Department of Community Health Sciences, Department of Medicine]
2001-present	Neurology faculty. Alberta Health Services, Calgary Zone
2003-07	Neurology Visiting Faculty. Medicine Hat Regional Hospital
1997-99	Medical Staff. Toronto East General Hospital

Selected Honours / Distinctions (Last 5 years)

2022	Officer of the Order of Canada
2022	Queen Elizabeth II's Platinum Jubilee Medal (Alberta)
2021	Canadian Society for Clinical Investigation (CSCI) Distinguished Scientist Award and Lecture
2021	Fellow of the Royal Society of Canada (FRCS)
2021	Canadian Society for Clinical Investigation (CSCI) Distinguished Scientist Award

2021	and Lecture Cumming School of Medicine's Smith Distinguished Achievement Award <i>This Award recognizes the extraordinary contribution made by you to the Cumming School of Medicine over the past two years. Such recognition is given to only a few of our faculty and is awarded to you for outstanding contributions by a senior faculty member.</i>
2020	Science Breakthrough Award. American Brain Foundation. ESCAPE Trial – <i>awarded to Andrew Demchuk, Mayank Goyal, Michael Hill</i>
2018	Killam Annual Professor Award

Experience Working in Collaborative Projects

Cardiovascular and Stroke SCN. Senior Medical Director.

ESCAPE-NEXT trial. This trial is has completed enrolment, global at 85 sites.

ESCAPE-NA1 trial. This is a completed phase 3 randomized controlled trial to assess treatment of acute stroke with nerinetide vs. placebo. There were 48 active sites internationally in Canada, US, UK, Europe, Australia and South Korea

ESCAPE trial. This is a completed phase 3 randomized controlled trial to assess the treatment of acute stroke with endovascular therapy. There were 22 active site internationally in Canada, US, UK, Europe and South Korea.

TEMPO-2 trial. This is a current phase 3 cohort study to assess the use of TNK-TPA for the treatment of minor stroke. There 35 active sites in internationally.

Major Grants in the Past 5 Years

1. ESCAPE-NEXT trial. Principal Investigator. \$1,600,000 (2022-2025) from CIHR, \$15M from NoNO Inc.. Phase 3 randomized clinical trial - CIHR project scheme grant
2. TEMPO-2 trial. Co-Principal Investigator. \$1,992,825.00 (2018-2023). Phase 3 randomized clinical trial - A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion.. Funded by CIHR.
3. ESCAPE-NA1 trial. Principal Investigator. \$2,138,245.00 (2016-2019) from CIHR, \$13M from NoNO Inc.. Phase 3 randomized clinical trial - Extension of Stroke Care by Added neuroProtection to Endovascular Treatment (ESCAPE-NA1). CIHR project scheme grant
4. QuICR group. Principal Investigator. \$5M. 2014-2019. Program grant for Alberta to improve acute stroke care. Funded by Alberta Innovates Health Solutions.

PUBLICATIONS

Peer-reviewed = 850 [Original Research Manuscripts (670), Reviews, Guidelines (91), Editorials, Opinions (89)]

Other = 678 [Book Chapters, Reviews - Non-peer-reviewed (17), Abstracts, Conference Proceedings, Letters, Notes (661)]

ISI Web of Science (10 Feb 2024) Total citations = 60553; Average Citations per Item= 47.13; H-index= 113

Google Scholar (10 Feb 2024) Total citations = 89328; i10-index= 668; H-index= 137;

ORCID: 0000-0002-6269-1543 Web of Science ResearcherID: C-9073-2012